晚期转移性食管癌一线治疗方案临床疗效的网状Meta分析OA

Objective To evaluate the efficacy of immunotherapy,radiotherapy,chemotherapy,and targeted therapy as first-line treatment regimens in patients with advanced metastatic esophageal cancer.Methods By systematically searching multiple databases such as PubMed,Embase,and Cochrane Library,information on different treatment options for advanced metastatic esophageal cancer was collected and analyzed.Cochrane risk-of-bias tool(RevMan 5.4)was employed to evaluate the quality of the included literature,and RStudio and RevMan 5.4 software were conducted to a network meta-analysis,to comprehensively evaluate the efficacy of different treatment regimens.This study used Bayesian model for frequency analysis,to complete the corresponding network meta-analysis.Results A total of 60 studies were included,involving 24 681 patients and 42 different treatment options.Among them,there are 27 randomized controlled trials involving 9 730 patients.The results showed that the combination of immunotherapy and chemotherapy ranked well,among which the"durvalumab+tremelimumab+paclitaxel+cisplatin"regimen,"camrelizumab+paclitaxel+cisplatin"regimen,and"toripalimab+paclitaxel+cisplatin"regimen all achieved good progression-free survival advantages.Conclusion In patients with advanced metastatic esophageal cancer,immunotherapy combined with chemotherapy yielded superior progression-free survival compared to both conventional chemotherapy and chemotherapy combined with targeted therapy.